COVID-19 presents important challenges for people affected by Scleroderma. This page provides available resources and pertinent information for Scleroderma patients, as well as initiatives to support the organization and patients during these difficult times.
BC CDC 3rd Dose Eligibility, as of 2021 October 16
Individuals with an autoimmune disorder per se in BC are not eligible for a COVID-19 vaccine 3rd dose unless they are receiving …
Active treatment with the following immunosuppressive therapies:
- People who received treatment since January 2020 with any anti-CD20 agents (such as rituximab, ocrelizumab, ofatumumab, obinutuzumab, ibritumomab, tositumomab).
- People who have been treated since January 2020 with b-cell depleting agents (such as epratuzumab, MEDI-551, belimumab, BR3-Fc, AMG-623, Atacicept, anti-BR3, alemtuzumab).
- People who have been treated with biologics since December 15, 2020: abatacept, adalimumab, anakinra, benralizumab, brodalumab, canakinumab, certolizumab, dupilumab, etanercept, golimumab, guselkumab, infliximab, interferon products (alpha, beta, and pegylated forms), ixekizumab, mepolizumab, natalizumab, omalizumab, resilizumab, risankizumab, sarilumab, secukinumab, tildrakizumab, tocilizumab, ustekinumab, or vedolizumab.
- People who have been treated with oral immune-suppressing drugs since December 15, 2020: azathioprine, baricitinib, cyclophosphamide, cyclosporine, leflunomide, dimethyl fumerate, everolimus, fingolimod, mycophenolate, siponimod, sirolimus, tacrolimus, tofacitinib, upadacitinib, methotrexate, dexamethasone, hydrocortisone, prednisone, methylprednisolone, or teriflunomide.
- People who have been treated with steroids orally or by injection on an ongoing basis since December 15, 2020: dexamethasone, hydrocortisone, methylprednisolone, or prednisone.
- People who have been treated with immune-suppressing Infusions/injections since December 15, 2020: cladribine, cyclophosphamide, glatiramer, methotrexate.
For individuals with scleroderma, the typical therapies from the list above include rituximab, abatacept, tocilizumab, azathioprine, cyclophosphamide, mycophenolate, tacrolimus, methotrexate, dexamethasone, hydrocortisone, prednisone, and methylprednisolone. Note that there are dates associated with administration of these therapies that also must be satisfied in order to receive a 3rd dose.
Check with your doctor about receiving the 3rd dose.
With the approval of two vaccines in Canada for Covid-19, there are many questions about the safety and efficacy of the vaccines for people living with scleroderma.
Dealing with COVID & Vaccines
The discussion was held on February 11, 2021 and now the video is available to you.
Dr. Janet Pope – Dr. Mark Larche – Dr. John Varga – Maureen Sauve
Dr. Brett D. Thombs
American College of Rheumatology
One item in the video was reference to the American College of Rheumatology Guidance Related to the Use and Timing of Vaccination and Immunomodulatory Therapies in Relation to COVID-19 Vaccination Administration in Rheumatoid Arthritis Patients
You can have a look at COVID-19 Vaccine Clinical Guidance Summary
NOTE, PLEASE MAKE SURE YOU DISCUSS THIS WITH YOUR DOCTOR.
SPIN Series: Living with Covid
Thanks to the success of the SPIN-CHAT (COVID-19 Home-isolation Activities Together) Program and in response to public demand, we decided to offer weekly webinars of our educational segments! Starting February 2nd and held every Wednesday 4-5 PM PST thereafter, for a total of 11 webinars. Take a look at our presentation line-up below:
|Mar 03||Home activity engagement||Laura Bustamante|
|Mar 10||Worry management (Part 2)||Ghassan El-Baalbaki|
|Mar 17||Relaxation techniques (Part 2)||Ghassan El-Baalbaki|
|Mar 24||Adapted home exercise (Part 2)||Kelsey Ellis & Delaney Duchek|
|Mar 31||Home activity engagement (Part 2)||Laura Bustamante|
|Apr 07||Worry management (Part 3)||Ghassan El-Baalbaki|
|Apr 14||Adapted home exercise (Part 3)||Kelsey Ellis & Delaney Duchek|
For the first session REGISTER HERE
COVID-19 presents important challenges for people affected by Scleroderma. This page puts together available resources and pertinent information for Scleroderma patients, as well as the initiatives to support the organization and patients during these difficult times.
Scleroderma and the COVID vaccine.
Scleroderma Foundation in the United States pulled together a talented group of experts and have provided a page with information and recommendations on COVID-19 vaccines. Read what some of the top experts in the world have to say: READ HERE
Answers to your questions!
Immunosuppression is a risk factor, and having an interstitial lung disease (ILD) or Scleroderma without an ILD puts you at a slightly higher risk.
You have questions? Please view this videoforum captured on March 21 2020.
« Scleroderma & COVID-19 : A conversation with the experts »
Participants were invited to submit their questions concerning COVID-19 and Scleroderma in advance via an online Qualtrics questionnaire or to ask their questions directly to a team of five experienced panelists. Mrs. Maureen Sauvé, Dr. Janet Pope, Dr. John Varga, Dr. Don Sheppard and Dr. Brett Thombs. By typing them into the discussion section of GotoMeeting.
Make the difference!
Every donation and effort help us to make a difference to advance research and to support people affected by scleroderma in British Columbia.
Support research and scleroderma patients!